Treat and Prevent Migraines with an All-in-One Medication

Friday, June 10, 2022 7:30 PM to 8:30 PM · 1 hr. (America/Denver)

Industry Event

Information

Industry-Sponsored Event

Sponsored by Biohaven Pharmaceuticals

Not Eligible for CME Credits

Peter McAllister, MD
New England Center for Neurology and Headache

Biohaven is a biopharmaceutical company focused on the development and commercialization of innovative best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases.

Biohaven Pharmaceuticals313Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases. The Company has two small molecule calcitonin gene-related peptide (CGRP) receptor antagonist product candidates in development, rimegepant and vazegepant, for acute and preventive treatment of migraine. Rimegepant, the lead candidate, is an orally-administered, rapidly dissolving single dose CGRP with a novel mechanism that targets the underlying pathophysiology of migraine without causing vasoconstriction. For more information, visit www.biohavenpharma.com.

Treat and Prevent Migraines with an All-in-One Medication

Information

Sponsored by Biohaven Pharmaceuticals

Log in